Compare PAI & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | ATRA |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.7M | 94.2M |
| IPO Year | N/A | 2014 |
| Metric | PAI | ATRA |
|---|---|---|
| Price | $11.30 | $9.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 21.9K | ★ 33.1K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.25 | $3.92 |
| 52 Week High | $12.95 | $19.15 |
| Indicator | PAI | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 26.56 | 54.10 |
| Support Level | N/A | $8.96 |
| Resistance Level | $12.35 | $10.02 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 15.29 | 85.20 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.